Montelukast

Highest phase reached

Approved

www.ebi.ac.uk

Drug type

Small molecule

www.ebi.ac.uk

First approval year

1998

www.ebi.ac.uk

First approval year: 1998
www.ebi.ac.uk

Listing at source: Listed

Highest phase reached: Approved
www.ebi.ac.uk

Drug type: Small molecule
www.ebi.ac.uk

Drug name: Montelukast
www.ebi.ac.uk

Molecular weight: 586.2
www.ebi.ac.uk

Structure (SMILES): CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1
www.ebi.ac.uk

singulair
Singulair

brondilat
Brondilat
cyclopropaneacetic acid 1 1r 1 3 e 2 7 chloro 2 quinolinyl ethenyl phenyl 3 2 1 hydroxy 1 methylethyl phenyl propyl thio methyl
CYCLOPROPANEACETIC ACID, 1-((((1R)-1-(3-((E)-2-(7-CHLORO-2-QUINOLINYL)ETHENYL)PHENYL)-3-(2-(1-HYDROXY-1-METHYLETHYL)PHENYL)PROPYL)THIO)METHYL)-
montelukast
Montelukast
MONTELUKAST [HSDB]
montelukast [INN]
MONTELUKAST [MI]
MONTELUKAST [VANDF]
Montelukast [WHO-DD]
montelukast hsdb
montelukast inn
montelukast mi
montelukast vandf
montelukast who dd

CAS registry numbers

158966-92-8

ChEMBL ID: CHEMBL787
www.ebi.ac.uk

InChIKey: UCHDWCPVSPXUMX-TZIWLTJVSA-N
www.ebi.ac.uk

PubChem compound IDs

5281040

RxNorm IDs (RxCUI)

88249

FDA ingredient codes (UNII)

MHM278SD3E

R03DC03
R03DC53

Sources for recorded values

www.ebi.ac.uk

Applicant: ORGANON
Approval date: 20 Feb 1998
Application number: NDA020829

First in class: No
Orphan designation: No
Availability: Prescription only
Boxed warning: Yes

United States (FDA): Approved

Pharmacology name: montelukast
Type: Synthetic organic
Drug name stem: -ast
Approval recorded by Guide to Pharmacology: Yes

Administration routes

Oral

Action
Antagonist
Action type
Antagonist
Target
CysLT1 receptor
Gene symbol
CYSLTR1
Protein identifier
Q9Y271
Affinity units
pIC50
Primary target
Yes
Action
Antagonist
Action type
Antagonist
Target
CysLT1 receptor
Gene symbol
CYSLTR1
Protein identifier
Q9Y271
Median affinity
8.64
Affinity units
pIC50
Primary target
Yes
Action
Antagonist
Action type
Antagonist
Target
CysLT1 receptor
Gene symbol
CYSLTR1
Protein identifier
Q9Y271
Median affinity
8.55
Affinity units
pKi
Primary target
Yes

Open Targets mechanisms

Mechanism
Cysteinyl leukotriene receptor 1 antagonist
Action type
Antagonist
Target
Cysteinyl leukotriene receptor 1

DrugCentral mechanisms

Action type
Antagonist
Gene symbol
CYSLTR1
Protein identifier
Q9Y271
Organism
Homo sapiens
Target development level
Clinical

Condition
Diabetic Nephropathies
Highest recorded phase
3
Condition identifier
EFO:0000401
Subject identifier
D003928
Condition
Immune System Diseases
Highest recorded phase
1
Condition identifier
EFO:0000540
Subject identifier
D007154
Condition
Respiratory Tract Diseases
Highest recorded phase
1
Condition identifier
EFO:0000684
Subject identifier
D012140
Condition
Arthritis, Rheumatoid
Highest recorded phase
3
Condition identifier
EFO:0000685
Subject identifier
D001172
Condition
Severe Acute Respiratory Syndrome
Highest recorded phase
3
Condition identifier
EFO:0000694
Subject identifier
D045169
Condition
HIV Infections
Highest recorded phase
1
Condition identifier
EFO:0000764
Subject identifier
D015658
Condition
Multiple Myeloma
Highest recorded phase
3
Condition identifier
EFO:0001378
Subject identifier
D009101
Condition
Carcinoma, Non-Small-Cell Lung
Highest recorded phase
2
Condition identifier
EFO:0003060
Subject identifier
D002289
Condition
Pain
Highest recorded phase
3
Condition identifier
EFO:0003843
Subject identifier
D010146
Condition
Sleep Apnea Syndromes
Highest recorded phase
2
Condition identifier
EFO:0003877
Subject identifier
D012891
Condition
Acne Vulgaris
Highest recorded phase
3
Condition identifier
EFO:0003894
Subject identifier
D000152
Condition
Premature Birth
Highest recorded phase
2
Condition identifier
EFO:0003917
Subject identifier
D047928
Condition
Sleep Apnea, Obstructive
Highest recorded phase
3
Condition identifier
EFO:0003918
Subject identifier
D020181
Condition
Rhinitis, Allergic, Seasonal
Highest recorded phase
4
Condition identifier
EFO:0003956
Subject identifier
D006255
Condition
Severe Dengue
Highest recorded phase
2
Condition identifier
EFO:0004227
Subject identifier
D019595
Condition
Eosinophilic Esophagitis
Highest recorded phase
3
Condition identifier
EFO:0004232
Subject identifier
D057765
Condition
Rhinitis, Allergic, Seasonal
Highest recorded phase
4
Condition identifier
EFO:0005854
Subject identifier
D006255
Condition
Rhinitis, Allergic
Highest recorded phase
4
Condition identifier
EFO:0005854
Subject identifier
D065631
Condition
Persian Gulf Syndrome
Highest recorded phase
1
Condition identifier
EFO:0007430
Subject identifier
D018923
Condition
Status Asthmaticus
Highest recorded phase
2
Condition identifier
EFO:0008590
Subject identifier
D013224
Condition
Respiratory Sounds
Highest recorded phase
3
Condition identifier
EFO:0009715
Subject identifier
D012135
Condition
Non-alcoholic Fatty Liver Disease
Highest recorded phase
1
Condition identifier
EFO:1001249
Subject identifier
D065626
Condition
Rhinitis, Allergic, Perennial
Highest recorded phase
3
Condition identifier
EFO:1001417
Subject identifier
D012221
Condition
Lung Diseases, Obstructive
Highest recorded phase
4
Condition identifier
HP:0006536
Subject identifier
D008173
Condition
Cough
Highest recorded phase
2
Condition identifier
HP:0012735
Subject identifier
D003371

And 7 more, listed on the interactive page.

Condition identifier
EFO_0000274
Condition identifier
EFO_0000401
Highest recorded phase
3
Condition identifier
EFO_0000540
Condition identifier
EFO_0000612
Highest recorded phase
3
Condition identifier
EFO_0000684
Highest recorded phase
1
Condition identifier
EFO_0000685
Highest recorded phase
3
Condition identifier
EFO_0001378
Highest recorded phase
3
Condition identifier
EFO_0001645
Condition identifier
EFO_0003877
Condition identifier
EFO_0003884
Condition identifier
EFO_0003894
Highest recorded phase
3
Condition identifier
EFO_0003917
Highest recorded phase
2
Condition identifier
EFO_0003918
Highest recorded phase
3
Condition identifier
EFO_0003956
Condition identifier
EFO_0004227
Condition identifier
EFO_0004232
Condition identifier
EFO_0004255
Condition identifier
EFO_0005854
Condition identifier
EFO_0006834
Highest recorded phase
2
Condition identifier
EFO_0007430
Highest recorded phase
1
Condition identifier
EFO_0008590
Condition identifier
EFO_0010638
Highest recorded phase
2
Condition identifier
EFO_1001249
Condition identifier
EFO_1001417
Highest recorded phase
3
Condition identifier
EFO_1001461

And 61 more, listed on the interactive page.

Warning
Black Box Warning
Warning
Black Box Warning
Effect
neurotoxicity

Warning
Black Box Warning
Country
United States
Warning
Black Box Warning
Effect
cardiotoxicity
Country
United States
Warning
Black Box Warning
Effect
neurotoxicity
Country
United States
Warning
Black Box Warning
Effect
psychiatric toxicity
Country
United States

Event
abnormal behaviour
Reports
426
Reporting signal score
742.487
Event
aggression
Reports
547
Reporting signal score
964.053
Event
allergic granulomatous angiitis
Reports
510
Reporting signal score
2,426.83
Event
anger
Reports
241
Reporting signal score
413.977
Event
anxiety
Reports
664
Reporting signal score
536.836
Event
asthma
Reports
2,255
Reporting signal score
6,293.98
Event
blood count abnormal
Reports
449
Reporting signal score
1,120.29
Event
blood test abnormal
Reports
125
Reporting signal score
221.778
Event
breath sounds abnormal
Reports
95
Reporting signal score
222.105
Event
bronchial obstruction
Reports
56
Reporting signal score
157.317
Event
bronchial secretion retention
Reports
53
Reporting signal score
179.958
Event
bronchial wall thickening
Reports
45
Reporting signal score
154.813
Event
bronchiectasis
Reports
89
Reporting signal score
168.129
Event
bursitis
Reports
114
Reporting signal score
204.674
Event
chest discomfort
Reports
459
Reporting signal score
477.558
Event
chronic spontaneous urticaria
Reports
46
Reporting signal score
153.24
Event
coeliac disease
Reports
126
Reporting signal score
303.126
Event
cough
Reports
873
Reporting signal score
738.626
Event
crying
Reports
190
Reporting signal score
280.506
Event
depressed mood
Reports
180
Reporting signal score
187.417
Event
depression
Reports
653
Reporting signal score
530.235
Event
dyspnoea
Reports
1,520
Reporting signal score
1,008.74
Event
dyspnoea exertional
Reports
265
Reporting signal score
358.257
Event
eosinophil count increased
Reports
162
Reporting signal score
341.828
Event
eosinophilia
Reports
234
Reporting signal score
365.762

And 41 more, listed on the interactive page.

NCT00045955
clinicaltrials.gov
NCT00090142
clinicaltrials.gov
NCT00092092
clinicaltrials.gov
NCT00092131
clinicaltrials.gov
NCT00116324
clinicaltrials.gov
NCT00148408
clinicaltrials.gov
NCT00156819
clinicaltrials.gov
NCT00196547
clinicaltrials.gov
NCT00213252
clinicaltrials.gov
NCT00245570
clinicaltrials.gov
NCT00296491
clinicaltrials.gov
NCT00296530
clinicaltrials.gov
NCT00311051
clinicaltrials.gov
NCT00328718
clinicaltrials.gov
NCT00380484
clinicaltrials.gov
NCT00394355
clinicaltrials.gov
NCT00395304
clinicaltrials.gov
NCT00461032
clinicaltrials.gov
NCT00462592
clinicaltrials.gov
NCT00471809
clinicaltrials.gov
NCT00490243
clinicaltrials.gov
NCT00543686
clinicaltrials.gov
NCT00565955
clinicaltrials.gov
NCT00636207
clinicaltrials.gov
NCT00666679
clinicaltrials.gov

And 106 more, listed on the interactive page.

Dose: 10mg
Route: Oral
How often: Once daily in the evening

If missed, take at the next scheduled dose, do not double the dose
Take with or without food

Hydrogen bond acceptors: 4
Hydrogen bond donors: 2
Polar surface area: 70.42
Calculated partition coefficient (ALogP): 8.95
Calculated partition coefficient (XLogP): 7.7
Prodrug: No
Chirality: Single enantiomer
Inorganic: No
Rule-of-five violations: 2
Rotatable bonds: 12
Heavy atoms: 41
Molecular formula: C35H36ClNO3S
Monoisotopic mass: 585.2104429
Natural product: Yes

31722-727
31722-728
33342-110
33342-111
72189-223
50090-2921
50090-4705
50090-7920
50090-7925
68788-7669

Recorded assays: 540
Active assays: 67

Confirmatory
Other
Screening

Anti-Asthmatic Agents
id.nlm.nih.gov
Leukotriene Antagonists
id.nlm.nih.gov
Cytochrome P-450 CYP1A2 Inducers
id.nlm.nih.gov

Oral bioavailability

Median: 63
Mean: 59.3333
Minimum: 42
Maximum: 73
Unit: %
Assays: 3
Standard deviation: 15.8219
Summary method: median
Censored results excluded: 0
Other units excluded: 0
Unknown units excluded: 0

Measurement types

Related records

Trials (233)

A Clinical Trial to Evaluate MK-4208/Embibatinib in Healthy Adult Participants (MK-4208-001/Embibatinib-1014)
A Clinical Trial to Test How Well Two Drugs, QAW039 and Montelukast Work Both Individually and Together, to Target Allergic Rhinitis Using an Environmental Exposure Chamber
A Dose-Ranging Study of MK-1029 in Adults With Persistent Asthma (MK-1029-012)
A Drug Interaction Study of Montelukast and Levocetirizine
A Mechanistic Study to Evaluate the Efficacy of Montelukast on Airway Function in Asthma
A Phase 1 Drug-drug Interaction Study in Healthy Volunteers
A Pilot Study of Mirabegron and Montelukast in Cirrhotic Patients
A Pilot Study to Determine the Feasibility and Utility of Implementing of the Full Scale TOM Trial
A Pilot Study to Evaluate the Efficacy of Montelukast in the Treatment of Acute Otitis Media (AOM) in Children
A Placebo and Active Controlled Study of ONO-6950 Following Allergen Challenge in Patients With Asthma
A Placebo and Active Controlled Study of ONO-6950 in Asthmatic Patients
A Prospective Study to Investigate Safety and Tolerability of Shorter Infusion of Fabrazyme
A Study Evaluating the Efficacy and Safety of Lebrikizumab in Adult Patients With Mild to Moderate Asthma
A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma
A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma
A Study of MK0476 in the Treatment of Asthma Patients Aged 2-5 Years (0476-907)
A Study to Assess the Effect of BMS-986142 on Pharmacokinetics (PK) of Probe Substrates
A Study To Assess The Effect Of PF-03893787 On Lung Function Following An Allergen Challenge In Asthmatic Subjects
A Study to Evaluate Efficacy and Safety of ADC3680 in Subjects With Inadequately-Controlled Asthma
A Study to Evaluate the Drug-drug Interaction Potential of BMS-986196 in Healthy Participants

Approved for (4)

Allergic rhinitis
Asthma
Obstructive lung disease
Seasonal allergic rhinitis

In development for (39)

Acne Phase 3
Allergic asthma Phase 2
Alzheimer disease Phase 2
Brain neoplasm Phase 1
Bronchiolitis Phase 2
Bronchiolitis obliterans syndrome Phase 2
Bronchopulmonary dysplasia Phase 1
Chronic graft versus host disease Phase 2
Chronic obstructive pulmonary disease Phase 2
Colorectal cancer Phase 1
COVID-19 Phase 3
Dengue disease Phase 2
Dengue hemorrhagic fever Phase 2
Diabetic kidney disease Phase 3
Endometrial cancer Phase 1
Eosinophilic esophagitis Phase 3
Fatty liver disease Phase 1
HIV infectious disease Phase 1
Immune system disorder Phase 1
Metabolic dysfunction-associated steatohepatitis Phase 1

Targets (1)

CYSLTR1 Cysteinyl leukotriene receptor 1 antagonist

Montelukast

Development status

Names and chemistry

Brand names (2)

Other names (16)

Identifiers

ATC classification codes (2)

Regulatory information

United States

Other regulatory facts

Approval status

Pharmacology

Drug classification

Administration routes

Mechanisms of action (3)

Open Targets mechanisms

DrugCentral mechanisms

Investigated indications (32)

Open Targets indications (86)

Warnings (2)

Open Targets warnings (4)

Reported adverse events (66)

Trial references (131)

Dosing

Conditions of use (2)

Chemical properties

National Drug Codes

Evidence counts

Active assay types (3)

Pharmacologic actions

Biological measurements

Observed measurements

Oral bioavailability

Measurement types

Related records

Trials (233)

Approved for (4)

In development for (39)

Other linked conditions (9)

Targets (1)